Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
The Translational Revolution in Inflammatory Skin Diseases
Description
The presentation discusses the advancements in the treatment of various inflammatory skin diseases, highlighting the rapid progress in understanding the pathogenesis and treatment options for conditions such as psoriasis, atopic dermatitis, alopecia areata, generalized pustular psoriasis, and pyoderma gangrenosum. It explains the shift in treatment focus from keratinocyte dysfunction to the role of the immune system, particularly in psoriasis, where targeted therapies like IL-17 and IL-23 inhibitors have shown remarkable efficacy. The speaker shares influential research and personal patient cases illustrating the transformative effects of newer therapies such as dupilumab for atopic dermatitis and innovative treatments like Janus kinase (JAK) inhibitors that effectively target multiple cytokines involved in these diseases. The presentation emphasizes the collaborative research efforts at Mount Sinai, revealing a promising future for patients suffering from these challenging skin conditions as we continue to uncover the intricacies of immune mechanisms and drug interventions.
View moreConclusions
- New treatments like JAK inhibitors significantly improve outcomes for various inflammatory skin diseases, such as psoriasis and atopic dermatitis.
- Blocking IL-23 is effective in managing psoriasis by inactivating TH-17 cells, which contribute to the disease's pathogenesis.
- Dramatic improvements have been observed in patients with psoriasis using IL-17 inhibitors, showcasing their efficacy.
- Topical and systemic therapies for atopic dermatitis provide effective relief, emphasizing the need for tailored patient treatment plans.
- Dupilumab has shown extraordinary effectiveness for atopic dermatitis by targeting IL-4 and IL-13 pathways.
- Patients with alopecia areata and atopic conditions show overlap, necessitating comprehensive treatment approaches based on individual patient profiles.
- Generalized pustular psoriasis can be treated effectively through IL-36 blockade, indicating a shift in treatment strategies.
- Baricitinib and other JAK inhibitors offer new therapeutic options for alopecia areata, demonstrating promising results in clinical trials.
- Nestle F, et al. NEJM 2009;361:496-509.
- Patel D, Lee D, Kolbinger F, et al. Ann Rheum Dis. 2013;72(Suppl 2):il116-23.
- Kridin K, Renert-Yuval Y, Guttman-Yassky E, Cohen AD. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1323-1328.e1.
- Song T, Pavel AB, Wen HC, Malik K, Estrada Y, Gonzalez J, Hashim PW, Nia JK, Baum D, Kimmel G, Singer GK, Krueger JG, Guttman-Yassky E. J Allergy Clin Immunol. 2018 Nov;142(5):1631-1634.e13.
- Czarnowicki T, He HY, Wen HC, Hashim PW, Nia JK, Malik K, Estrada Y, Kimmel GW, Taliercio M, Krueger JG, Guttman-Yassky E. Allergy. 2018 Mar;73(3):713-723.
- Gittler JK, Guttman-Yassky E. J Allergy Clin Immunol Sep 2012.
- Marrakchi S, et al. N Engl J Med. 2011; 365:620-8.
- Burns M, Orlowski M, Ho-Pham H, Elston C, Elewski B. SKIN,2023; 7:585-588.
- Bachelez H, et al. N Engl J Med. 2021;385:2431-40. DOI: 10.1056/NEJMoa2111563.
- Guénin, S. H., Khattri, S., & Lebwohl, M. G. (2023). Spesolimab Use in Treatment of Pyoderma Gangrenosum. JAAD Case Reports.
- Mesinkovska NA, et al. AAD 2022, P34007. Sponsored by Eli Lilly and Company.
- Casella J, et al. EADV 2019, D3T01.1E Sponsored by Concert Pharmaceuticals.
- Armstrong A, et al. Poster presented at AAD VMX 2021. Sponsored by BMS.